Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
The presented framework provides decision makers with insight into the financial consequences of their chosen payment model under different assumptions. This can aid reimbursement negotiations by clarifying the optimal choice given a therapy's characteristics.
Authors
- Wim Goettsch (ORCID: https://orcid.org/0000-0002-8022-7496)
- Rick A. Vreman (ORCID: https://orcid.org/0000-0002-2076-322X)
- Christine Leopold (ORCID: https://orcid.org/0000-0002-2046-8490)
- Marcelien Callenbach (ORCID: https://orcid.org/0000-0003-2293-0746)
- Aukje K. Mantel-Teeuwisse
Institutions
- Utrecht University (NL)
- National Health Care Institute (NL)
- Pharmo Institute (NL)
- Zorginstituut Nederland (NL)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1007/s40273-024-01433-4
- Citations
- 4
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 4.52
Funders
- Zorginstituut Nederland